NCT04798885 (GAIN2) is a NA clinical trial of GAIN 2.0 in Commotio Cerebri, sponsored by University of Aarhus.

Who is sponsoring NCT04798885?

NCT04798885 is sponsored by University of Aarhus.

What drugs are being tested in NCT04798885?

Interventions in NCT04798885: GAIN 2.0.

What condition does NCT04798885 study?

NCT04798885 studies Commotio Cerebri, Mild Traumatic Brain Injury.

Is NCT04798885 still recruiting?

NCT04798885 is currently status unknown. Last updated 13 November 2023.

Last reviewed 2023-11-13 · How we verify

NCT04798885: GAIN2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Get Going After concussioN 2.0

Status unknown NA Last updated 13 November 2023

What this trial tests

NA trial testing GAIN 2.0 in Commotio Cerebri in 310 participants. Status unknown.

Timeline

12 May 2021

Primary endpoint
1 June 2023

1 September 2024

Quick facts

Lead sponsor	University of Aarhus
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	310
Start date	12 May 2021
Primary completion	1 June 2023
Estimated completion	1 September 2024
Sites	1 location across Denmark

Drugs / interventions tested

GAIN 2.0

Conditions studied

Commotio Cerebri — all drugs for Commotio Cerebri →
Mild Traumatic Brain Injury — all drugs for Mild Traumatic Brain Injury →

Sponsor

University of Aarhus

Who can join

Adults 18 to 60, any sex, with Commotio Cerebri or Mild Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study tests the promising results of a previous study (GAIN 1.0) in a larger RCT (GAIN 2.0) which takes place in the municipalities of Central Denmark Region where citizens live their daily lives and whose health- and social care systems support citizens who experience persisting PCS.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interdisciplinary intervention (GAIN) for adults with post-concussion symptoms: a study protocol for a stepped-wedge cluster randomised trial.
Næss-Schmidt ET, Thastum MM, Stabel HH, Odgaard L, et al · · 2022 · cited 3× · PMID 35906645 · DOI 10.1186/s13063-022-06572-7

Verify or expand the search:

Other recruiting trials for Commotio Cerebri

Currently open trials in the same condition.

NCT05233475 — Get Going After concussIonN Lite · NA · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04798885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 13 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04798885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing